Showing results (51-60 of 92) with videos related to
Sort By:
Pageof 10
American Journal of Clinical Oncology|April 24, 2013
The association between tumor epidermal growth factor receptor (EGFR) mutation and multiple primary malignancies in patients with adenocarcinoma of the lungsYung-Hung Luo, Hsiang-Ling Ho, Chun-Ming Tsai, et al.Cancer Science|September 21, 2020
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAYMakoto Nishio, Takashi Seto, Martin Reck, et al.JTO Clinical and Research Reports|October 31, 2025
Incorporating High-Risk Individuals Beyond Smoking History Into Lung Cancer Screening in Hong Kong: A Cost-Effectiveness StudyHerbert Ho-Fung Loong, Xuanqi Pan, Carlos K H Wong, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patientsGee-Chen Chang, Chun-Ming Tsai, Kun-Chieh Chen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 31, 2019
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases AnalysisMyung-Ju Ahn, Chao-Hua Chiu, Ying Cheng, et al.Targeted Oncology|February 10, 2021
Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal MetastasisChi-Lu Chiang, Cheng-Chia Lee, Hsu-Ching Huang, et al.Plos One|October 8, 2020
Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancerHsiu-Ying Hung, Yen-Han Tseng, Heng-Sheng Chao, et al.Experimental and Therapeutic Medicine|September 13, 2012
Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutationsWen-Shuo Wu, Yuh-Min Chen, Chun-Ming Tsai, et al.Lung Cancer (Amsterdam, Netherlands)|March 12, 2024
Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER studyDong-Wan Kim, Byoung Chul Cho, Krishna Pachipala, et al.Thoracic Cancer|July 20, 2023
Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cell-derived organoidsYuan-Hung Wu, Heng-Sheng Chao, Chi-Lu Chiang, et al.Pageof 10